Palbociclib Capsules 125 Mg

Palbociclib Capsules 125 Mg is a targeted anticancer medication belonging to the class of CDK4/6 inhibitors, used in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It works by slowing down cancer cell division and is commonly used as a first-line targeted therapy in combination with hormonal treatments. In clinical practice, endocrine therapies such as Letrozole Tablets 2.5 Mg are frequently combined with Palbociclib to improve outcomes, while dose adjustments to Palbociclib Capsules 100 Mg may be made based on patient tolerance and safety profile.

Mechanism of Action

CDK4/6 Inhibition

Palbociclib Capsules 125 Mg inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are critical regulators of the cell cycle. By blocking these proteins, it prevents cancer cells from progressing from the G1 phase to the S phase, thereby halting cell division.

Tumor Growth Suppression

This targeted action helps slow tumor progression and enhances the effectiveness of hormonal therapies. For detailed research insights, refer to National Cancer Institute (NCI) and for safety information, consult Mayo Clinic – Palbociclib Drug Information.

Approved Medical Uses

Advanced Breast Cancer

Palbociclib Capsules 125 Mg is used in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Combination Therapy

It is typically prescribed in combination with endocrine therapy to delay disease progression and improve survival outcomes.

Dosage and Administration

Palbociclib Capsules 125 Mg is usually taken once daily for 21 consecutive days followed by a 7-day break, forming a 28-day cycle. The dosage should be taken exactly as prescribed by an oncologist. In combination therapy, Letrozole Tablets 2.5 Mg is commonly used to enhance treatment effectiveness, while dose reduction to Palbociclib Capsules 100 Mg may be required in patients experiencing side effects or tolerability issues.

Clinical Effectiveness

Clinical trials have demonstrated that Palbociclib Capsules 125 Mg significantly improves progression-free survival when combined with endocrine therapy. It is considered a standard first-line treatment in many advanced breast cancer cases.

Safety and Side Effects

Common Side Effects

• Neutropenia (low white blood cell count)
• Fatigue
• Nausea
• Hair thinning
• Infections

Serious Risks

• Severe neutropenia
• Increased risk of infections
• Lung inflammation (rare)

Regular blood monitoring is essential during treatment. For more safety details, refer to Mayo Clinic – Palbociclib Drug Information.

Contraindications and Precautions

Palbociclib Capsules 125 Mg should be used with caution in patients with:

• Low blood cell counts
• Liver impairment
• Active infections

It is not recommended during pregnancy or breastfeeding. Strict medical supervision is required.

Drug Interactions

Palbociclib Capsules 125 Mg may interact with CYP3A inhibitors/inducers, certain antibiotics, antifungals, and other anticancer drugs. Patients should inform their healthcare provider about all medications they are taking. For research-based information, refer to National Cancer Institute (NCI).

FAQs